08-14-2009: Epigenomics AG announced that it signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker Septin 9 (mSEPT9) with Salt Lake City, Utah, U.S. based ARUP Laboratories, Inc. (ARUP). Under the agreement, ARUP has obtained rights to use the mSEPT9 biomarker to develop a molecular-based laboratory test that can help physicians detect colorectal cancer based on a patient's blood sample.
"Having a simple blood test that can detect colorectal cancer will be a major step in the fight against this dreadful disease, which is often curable when caught in the early stages," said Ronald L. Weiss, MD, MBA, ARUP Executive Vice President of Health Policy, External Affairs, and Corporate Communication. "Patient compliance in the U.S with current colorectal cancer screening guidelines leaves a lot to be desired. All too often, patients fail to undergo a colonoscopy or conduct other types of colorectal cancer screenings because they find these methods invasive, unpleasant or costly. A blood test for detecting colorectal cancer, will be a convenient option that complements other screening methods."
ARUP is the second commercial laboratory in the U.S.A. to non-exclusively license the mSEPT9 biomarker from Epigenomics with the goal of commercializing a laboratory-developed blood test.
Contact / Request information
Request further information free of charge:
Epigenomics Biomarker Predicts Drug Resistance in Colorectal Cancer
Epigenomics AG announced the publication of a study authored by Professor Matthias Ebert at University of Heidelberg entitled “TFAP2E-DKK4 and Chemoresistance in Colorectal Cancer” in The New England Journal of Medicine.In this study involving more than 200 patients in four independent coho ... more
Epigenomics AG: Noel Doheny Appointed as New CEO of US-Subsidiary Epigenomics Inc.
Epigenomics AG announced the appointment of Noel Doheny as the new Chief Executive Officer (CEO) of its subsidiary Epigenomics Inc. in Seattle, WA, USA, reporting to Geert Nygaard, CEO of Epigenomics AG. Mr. Doheny will start in his new position in early May 2011. Mr. Doheny has 30+ years o ... more
Epigenomics AG and NextPharma Sign Global Manufacturing Deal for Colorectal Cancer Blood Test
Epigenomics AG and NextPharma Technologies announced that the companies have signed a global manufacturing contract for Epigenomics' Epi proColon product. Epi proColon, currently marketed in Europe, is the world's first in-vitro diagnostic test for the detection of colorectal cancer in a s ... more
Epigenomics AG reports that its licensee ARUP Laboratories, Salt Lake City, UT, U.S.A., today has announced the launched of a laboratory-developed test for the blood-based detection of colorectal cancer. The test is based on Epigenomics' proprietary Septin9 biomarker and DNA methylation tec ... more
Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test to ARUP Laboratories
Epigenomics AG announced that it signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker Septin 9 (mSEPT9) with Salt Lake City, Utah, U.S. based ARUP Laboratories, Inc. (ARUP). Under the agreement, ARUP has obtained rights to use the mSEPT9 biomarker to deve ... more
About analytica-world.com
analytica-world.com is the industry portal of the international trade fair analytica, which is organized by Messe München. It features useful information about markets, trends and innovations. It is operated by CHEMIE.DE, one of analytica's official sales partners.
Advertising at analytica-world.com
Our advertising formats support you in getting your message across to a clearly defined target audience.
The global network of analytica trade fairs:
